Bibliography
- AKDIS CA, BLASER K: Histamine in the immune regulation of allergic inflammation. J. Allergy Clin. Immunol. (2003) 112(1):15-22.
- SCHNEIDER E, ROLLI-DERKINDEREN M, AROCK M et al.: Trends in histamine research: new functions during immune responses and hematopoiesis. Trends Immunol. (2002) 23(5):255-263.
- MACGLASHAN D: Histamine: a mediator of inflammation. J. Allergy Clin. Immunol. (2003) 112(4):S53-S59.
- BERGER WE: Overview of allergic rhinitis. Ann. Allergy Asthma Immunol. (2003) 90:7-12.
- BOUSQUET J, ARIA WORKSHOP GROUP: Allergic rhinitis and its impact on asthma. J. Allergy Clin. Immunol. (2001) 108(5):S147-S334.
- SIMONS FE: Advances in H1-antihistamines. N. Engl. J. Med. (2004) 351:2202-2217.
- TOGIAS A: H1-receptors: localization and role in airway physiology and in immune functions. J. Allergy Clin. Immunol. (2003) 112(4):S60-S68.
- SIMONS FE: H1-antihistamines: more relevant than ever in the treatment of allergic disorders. J. Allergy Clin. Immunol. (2003) 112(4):S42-S52.
- LEURS R, SMIT MJ, TENSEN CP, TER LAAK AM, TIMMERMAN H: Site-directed mutagenesis of the histamine H1-receptor reveals the selective interaction of asparagine 207 with subclasses of H1 receptor agonists. Biochem. Biophys. Res. Commun. (1994) 201(1):295-301.
- BAKKER RA, WIELAND K, TIMMERMAN H, LEURS R: Constitutive activity of the histamine H1 receptor reveals inverse agonism of histamine H1 receptor antagonists. Eur. J. Pharmacol. (2000) 387(1):R5-R7.
- WALSH GM: The clinical relevance of the anti-inflammatory properties of antihistamines. Allergy (2000) 55(Suppl.60):53-61.
- STAUB A, BOVET D: Actions de la thymoethyl-diethylamine (929F) et des éthers phénoliques sur le choc anaphylactique de cobaye. CR Soc. Biol. (1937) 128:818-825.
- VAN-CAUWENBERGE P, BACHERT C, PASSALACQUA G et al.: Consensus statement on the treatment of allergic rhinitis. European Academy of Allergology and Clinical Immunology. Allergy (2000) 55(2):116-134.
- TIMMERMAN H: Factors involved in the absence of sedative effects by the second-generation antihistamines. Allergy (2000) 55(Suppl.60):5-10.
- DUBUSKE LM: Second-generation antihistamines: the risk of ventricular arrhythmias. Clin Ther. (1999) 21(2):281-295.
- SUESSBRICH H, WALDEGGER S, LANG F, BUSCH AE: Blockade of HERG channels expressed in Xenopus oocytes by the histamine receptor antagonists terfenadine and astemizole. FEBS Lett. (1996) 385(1-2):77-80.
- RENWICK AG: The metabolism of antihistamines and drug interactions: the role of cytochrome P450 enzymes. Clin. Exp. Allergy (1999) 29(Suppl.3):116-124.
- HOLGATE ST, CANONICA GW, SIMONS FEet al.: Consensus Group on New-Generation Antihistamines (CONGA): present status and recommendations. Clin. Exp. Allergy (2003) 33(9):1305-1324.
- CHRISTOPHE B, CARLIER B, GILLRAD M, CHATELAIN P, PECK M, MASSINGHAM R: Histamine H1 receptor antagonism by Cetirizine in isolated guinea pig tissues: influence of receptor reserve and dissociation kinetics. Eur. J. Pharmacol. (2003) 470(1-2):87-94.
- MCLEOD RL, MINGO GG, HEREZKU C et al.: Combined histamine H1 and H3 receptor blockade produces nasal decongestion in an experimental model of nasal congestion. Am. J. Rhinol. (1999) 13(5):391-399.
- ARRANG JM, GARBARG M, SCHWARTZ JC: Auto-inhibition of brain histamine release mediated by a novel class (H3) of histamine receptor. Nature (1983) 302(5911):832-837.
- LEURS R, BLANDINA P, TEDFORD C, TIMMERMAN H: Therapeutic potential of histamine H3 receptor agonists and antagonists. Trends Pharmacol. Sci. 19(5):177-183 (1998).
- MCLEOD RL, EGAN RW, CUSS FM, BOLSER DC, HEY JA: Histamine H3 antagonists. In: New Drugs for Asthma, Allergy and COPD. Hansel TT, Barnes PJ (Eds), Prog. Respir. Res., Karger, Basel, Switzerland (2001) 31:133-136.
- STARK H: Recent advances in histamine H3/H4 receptor ligands. Expert Opin. Ther. Patents (2003) 13(6):851-865.
- ELSNER J, ESCHER SE, FORSSMANN U: Chemokine receptor antagonists: a novel therapeutic approach in allergic diseases. Allergy (2004) 59(12):1243-1258.
- ERIN EM, WILLIAMS TJ, BARNES PJ, HANSEL TT: Eotaxin receptor (CCR3) antagonism in asthma and allergic disease. Curr. Drug Targets Inflamm. Allerg. (2002) 1(2):201-214.
- JUSTICE JP, BROCHERS MT, CROSBY JR et al.: Ablation of eosinophils leads to a reduction of allergen-induced pulmonary pathology. Am. J. Physiol. Lung Cell. Mol. Physiol. (2003) 284(1):L169-L178.
Patents
- AVENTIS PHARM.: US6407119 (2000).
- AMEDIS PHARM.: GB2394714 (2002).
- CIPLA: WO01178188 (2001).
- SUN PHARM.: WO03079970 (2003).
- SUN PHARM.: WO03087059 (2003).
- ALMIRALL PRODESFARMA: WO0236589 (2002).
- ALMIRALL PRODESFARMA: WO03082867 (2003).
- ALMIRALL PRODESFARMA: WO03099807 (2003).
- SUMITOMO PHARM.: WO2004026841 (2004).
- THERAVANCE: US6420560 (2002).
- SCHERING CORP.: WO0224657 (2002).
- SCHERING CORP.: WO0244141 (2002).
- SCHERING CORP.: WO0224658 (2002).
- SCHERING CORP.: WO0224659 (2002).
- GLAXO: WO2004035556 (2004).
- ASTRAZENECA: WO03024962 (2003).
- ASTRAZENECA: WO03068743 (2003).
- ASTRAZENECA: WO03004487 (2003).
- ASTRAZENECA: WO2004029041 (2004).